Compare TTC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTC | PTGX |
|---|---|---|
| Founded | 1914 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tools/Hardware | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 8.5B |
| IPO Year | 1994 | 2016 |
| Metric | TTC | PTGX |
|---|---|---|
| Price | $98.23 | $146.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $104.00 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 550.5K | 547.4K |
| Earning Date | 06-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 2.18 | ★ 2.35 |
| Revenue | ★ $2,618,650,000.00 | N/A |
| Revenue This Year | $6.13 | $874.25 |
| Revenue Next Year | $4.45 | N/A |
| P/E Ratio | ★ $45.38 | $2,746.40 |
| Revenue Growth | ★ 4.53 | N/A |
| 52 Week Low | $67.64 | $50.49 |
| 52 Week High | $105.19 | $143.29 |
| Indicator | TTC | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 63.12 | 63.87 |
| Support Level | $91.66 | $127.98 |
| Resistance Level | $102.32 | N/A |
| Average True Range (ATR) | 2.31 | 5.60 |
| MACD | 0.61 | -0.40 |
| Stochastic Oscillator | 94.65 | 93.64 |
The Toro Co designs, manufactures, markets, and sells professional turf maintenance equipment and services; turf and agricultural irrigation systems; landscaping equipment and lighting products; snow and ice management equipment; construction equipment; and residential yard and snow thrower products. The company operates through Professional and Residential segments, with the Professional segment serving commercial, agricultural, and construction customers and generating the majority of revenue, while the Residential segment focuses on homeowners. Its products are sold through distributors, dealers, retailers, rental centers, and direct channels, with the United States as its primary revenue-generating market.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.